摘要
目的评价帕瑞昔布钠联合舒芬太尼在骨科手术术中及术后的应用及安全性。方法 60例行椎体手术的患者随机分为两组,P组分别于术前15m in及12h后静脉睥瑞昔布钠40mg,C组分别给予生理盐水2m l。观察术后镇痛泵(PCA)舒芬太尼的用量、患者自控镇痛(PCA)的次数和有效次数,术后2、4、6、12、24h的VAS评分及不良反应。结果与C组相比,P组术后12h和24h舒芬太尼的用量减少,术后12h、24h PCA总次数和有效次数减少(P<0.05),术后4、6、12时的VAS评分降低(P<0.05),不良反应的发生率差异无统计学意义。结论椎体手术患者术日静脉给予帕瑞昔布钠40mgB id可减少术后PCA舒芬太尼用量,提高术后镇痛质量。
Objective To evaluate the application and security of parecoxib sodium combined with sufentanil in spinal surgery.Methods Totally 60 patients undergoing spinal surgery were randomly allocated to two groups：parecoxib group received intravenous parecoxib 40 mg 15min before the operation and 12 h after the first application and control group received normal saline instead of parecoxib.The patients in both groups received PCIA with sufentanil.VAS score,sufentanil consumption;the number of unsatisfied demand and the number of successfully delivered doses of PCA;and adverse effects were recorded.Results The sufentanil consumption at 12 hand 24 h after operation was significantly less in parecoxib group than that of control group.The number of unsatisfied demand and successfully delivered doses and VAS scores at the different time points were significantly lower in parecoxib group than that in control group.There were no serious adverse effects in both groups.Conclusion Parecoxib 40 mg given i.v.twice a day can reduce the sufentanil consumption and improve postoperative analgesia.
出处
《医药论坛杂志》
2010年第21期26-27,共2页
Journal of Medical Forum
